['relapsed ovarian cancer, brca mutation, platinum sensitivity']
['olaparib', 'single agent chemotherapy']

        Inclusion Criteria:

          -  Patients must be ≥ 18 years of age

          -  Patients with histologically diagnosed relapsed high grade serous ovarian cancer
             (including primary peritoneal and/or fallopian tube cancer) or high grade endometrioid
             cancer. Patients are eligible to undergo BRCA testing even if they have not yet had
             recurrence or progression of disease >6 months (>/=183 days) after completion of their
             last platinum therapy.

          -  Documented germline mutation in Breast Cancer susceptibility genes: BRCA1 and/or BRCA2
             that is predicted to be deleterious or suspected deleterious (known or predicted to be
             detrimental/lead to loss of function)

          -  At least one lesion that can be accurately assessed at baseline by CT/MRI and is
             suitable for repeated assessment.

          -  Patients must have received at least 2 prior platinum based lines of chemotherapy -
             Patients must be partially platinum sensitive or platinum sensitive

          -  Patients must be suitable to start treatment with single agent chemotherapy based on
             physician's choice

          -  Patients must have normal organ and bone marrow function measured within 28 days of
             randomisation,

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Patients must have a life expectancy ≥ 16 weeks

          -  Formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer
             must be available for central testing.

        Exclusion Criteria:

          -  BRCA 1 and/or BRCA2 mutations that are considered to be non detrimental

          -  Exposure to any investigational product within 30 days or 5 half lives (whichever is
             longer) prior to randomisation

          -  Any previous treatment with a Polyadenosine 5'diphosphoribose polymerisation (PARP)
             inhibitor, including olaparib.

          -  Patients who have platinum resistant or refractory disease

          -  Patients receiving any systemic chemotherapy within 3 weeks prior to first dose of
             study treatment

          -  Previous single agent exposure to the selected chemotherapy regimen for randomisation.
             - Prior malignancy in the last 5 years, unless curatively treated and recurrence free
             (few exceptions apply).
      